Daniel Duerschmied

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event

BackgroundPatients are at increased risk for recurrent ischemic events after an acute coronary syndrome event. Milvexian, an oral factor XIa inhibitor, may reduce the risk of major adverse clinical events with minimal bleeding risk. MethodsIn this phase 3, randomized, placebo-con...

Impact of CPAP and ventilator system resistance on respiratory effort in healthy volunteers

Abstract Introduction Continuous positive airway pressure (CPAP) is widely used for the treatment of acute and chronic respiratory failure and inspiratory support pressure (ΔP insp ) can be added to achieve non-invasive ventilation (NIV). We performed a physiological study to det...